Nontuberculous Mycobacterial (NTM) Lung Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Non-tuberculosis mycobacterial (NTM) lung infections are less prevalent than infections caused by Mycobacterium tuberculosis. The transmission of NTM occurs through the inhalation of aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include proximity living, coughing, and failure to use facial masks. Factors such as advanced age, immunosuppression, and corticosteroid usage increase the likelihood of acquiring NTM microorganisms. Following the entry into the body, NTM microorganisms predominantly settle in the lower airways and may induce an inflammatory response characterized by an influx of lymphocytes. This immune response releases cytokines and other mediators, resulting in a pneumonia-like infectious process. Common symptoms of NTM lung infections, such as fever, weight loss, night sweats, decreased appetite, and energy loss, are often nonspecific and vague. The prognosis of NTM lung infections is generally uncertain. Patients with compromised immune systems experience worse outcomes than those with normal immune function. Moreover, the prognosis may vary depending on the specific type of NTM infection. Recent research suggests that patients with NTM infections caused by Mycobacterium avium complex (MAC) generally have a more favorable prognosis than those with other NTM infections. Conversely, patients with Mycobacterial abscessus lung infections have higher mortality rates than patients with different NTM lung infections. Chronic underlying lung diseases, particularly Mycobacterial abscessus infection, in combination with the specific type of NTM infection, appear to be significant predictors of mortality in NTM lung infections. NTM lung disease typically presents in three major clinical forms: fibro-cavitary, nodular bronchiectasis, and hypersensitivity pneumonitis. The clinical manifestations of NTM lung infections can resemble those of other lung infections, such as Mycobacterium tuberculosis, as well as atypical bacterial infections and chronic lung diseases. Infections, neoplasms, and connective tissue diseases are common differential diagnoses similar to NTM lung infections.

·       In the USA, the incidence of NTM was estimated to be 4.73 cases per 100,000 annually.

Thelansis’s “Nontuberculous Mycobacterial (NTM) Lung Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Nontuberculous Mycobacterial (NTM) Lung Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Nontuberculous Mycobacterial (NTM) Lung Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Nontuberculous Mycobacterial (NTM) Lung Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Nontuberculous Mycobacterial (NTM) Lung Disease – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more